Clinical Trial Update: Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunogenicity, safety, and antibody persistence of a Beijing-produced COVID-19 booster vaccine in patients with hypertension an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• COVID-19 booster vaccine (Produced in Beijing)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19 Pneumonia | Phase 4 | Status: UNKNOWN